Home › Cancro al seno › Georgia › Atlanta
Studi clinici su Cancro al seno a Atlanta, GA
41 studi su Cancro al seno cercano partecipanti presso sedi a Atlanta e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
In reclutamentoFase 3
- Atlanta Cancer Care - Northside Hospital, Atlanta
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Atlanta VA Medical Center, Decatur · a 6 mi di distanza
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
In reclutamentoFase 2
- Winship Cancer Institute, Emory University, Atlanta
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
In reclutamentoFase 3
- Emory Proton Therapy Center, Atlanta
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
In reclutamentoFase 3
- Emory University Hospital, Atlanta
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
In reclutamentoFase 3
- Emory University Winship Cancer Institute, Atlanta
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
In reclutamentoFase 1
- Emory University School of Medicine - Winship Cancer Institute, Atlanta
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
In reclutamentoFase 2
- Winship Cancer Institute, Atlanta
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
In reclutamentoFase 1/2
- Winship Cancer Institute of Emory University, Atlanta
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
In reclutamentoFase 3
- Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
In reclutamentoFase 2
- Emory University (Data Collection Only), Atlanta
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
In reclutamentoFase 1/2
- Winship Cancer Institute of Emory University, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
In reclutamentoFase 1
- Emory University, Atlanta
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
In reclutamentoFase 2
- Emory University, Atlanta
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
In reclutamentoFase 3
- Winship Cancer Institute of Emory University, Atlanta
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
In reclutamentoFase 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Piedmont Hospital, Atlanta
- e altri 5
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
In reclutamentoFase 1
- Emory University - Winship Cancer Institute, Atlanta
Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
In reclutamentoVolontari sani benvenuti
- Emory University Hospital/Winship Cancer Institute, Atlanta
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
In reclutamentoFase 1
- Emory University, Atlanta
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
In reclutamentoFase 2
- Winship Cancer Institute at Emory University, Atlanta
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
In reclutamentoFase 2/3
- Northside Hospital, Atlanta
E-Mindfulness Approaches for Living After Breast Cancer
In reclutamentoFase 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- e altri 2
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
In reclutamentoFase 1/2
- Emory University, Atlanta
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
In reclutamentoFase 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
In reclutamentoFase 2
- GSK Investigational Site, Atlanta
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
In reclutamentoFase 3
- Emory University School of Medicine, Atlanta
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
In reclutamentoVolontari sani benvenuti
- Emory University Hospital/Winship Cancer Institute, Atlanta
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Emory University/Winship Cancer Institute, Atlanta
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
In reclutamentoFase 2
- Winship Cancer Institute of Emory University, Atlanta
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
In reclutamentoFase 3
- Emory University Hospital Midtown, Atlanta
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
In reclutamentoFase 2
- Emory University Winship Cancer Institute, Atlanta
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
In reclutamentoFase 3
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Piedmont Hospital, Atlanta
- e altri 5
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
In reclutamentoFase 1/2
- Research Site 111, Atlanta
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
In reclutamentoFase 1/2
- Emory Winship Cancer Institute, Atlanta
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
In reclutamentoStudio osservazionale
- Northside Hospital, Atlanta
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
In reclutamentoFase 1
- Emory University, Winship Cancer Institute, Atlanta
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
In reclutamentoFase 1
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- e altri 1
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Atlanta
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
In reclutamentoFase 3
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
In reclutamentoStudio osservazionale
- Piedmont Cancer Institute, Atlanta
- Emory University - Winship Cancer Institute, Atlanta
Studi su Cancro al seno in altre città
- New York City, NY136 studi
- Houston, TX126 studi
- Boston, MA112 studi
- Nashville, TN81 studi
- Los Angeles, CA73 studi
- Edison, NJ68 studi
- St. Louis, MO64 studi
- Queens, NY64 studi
- Durham, NC64 studi
- Chicago, IL59 studi
- Philadelphia, PA56 studi
- Dallas, TX55 studi
Altri studi a Atlanta
- Cancro (tutti i tipi)49 studi
- Cancro del polmone non a piccole cellule47 studi
- Mieloma multiplo42 studi
- Cancro alla prostata33 studi
- Leucemia mieloide acuta31 studi
- Cancro ovarico29 studi
- Cancro colorettale29 studi
- Cancro ai polmoni29 studi
- Cancro metastatico28 studi
- Disturbo depressivo maggiore25 studi
- Insufficienza cardiaca25 studi
- Carcinoma a cellule squamose della testa e del collo24 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.